MorphoSys Stock

MorphoSys FCF/Debt

Delisted

The Free Cash Flow to Debt Ratio of MorphoSys (MOR.DE) as of Aug 17, 2026 is -115.74 %. In the previous year, Free Cash Flow to Debt Ratio was -108.60 % — a change of 6.58% (lower).

FCF/Debt

-115.74 %

YoY

6.58%

Last updated:

Free Cash Flow to Debt Ratio of MorphoSys is 2026 -115.74 % . Free Cash Flow to Debt Ratio of MorphoSys was 2025 -108.60 % . It decreases by 6.58% lower compared to the previous year.
Access this data via the Eulerpool API

MorphoSys Stock analysis

What does MorphoSys do? MorphoSys AG is a biotech company based in Planegg near Munich, Germany, founded in 1992. The company specializes in the discovery and development of therapeutic antibodies and operates worldwide. MorphoSys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MorphoSys stock

Free Cash Flow to Debt Ratio of MorphoSys is -115.74 % in 2026.

Free Cash Flow to Debt Ratio of MorphoSys changed from -108.60 % to -115.74 %, representing a 6.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio MorphoSys since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's MorphoSys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — MorphoSys

All Key Metrics — MorphoSys